PanTheryx, Inc., a Boulder, Colorado-based medical nutrition company, raised $53m in financing.
Pegasus Capital Advisors made the investment.
The company intends to use the funds to support the global commercial launch of its infectious diarrhea product, DiaResQ®, to drive its ongoing research and development program, and for other strategic initiatives including acquisitions.
Founded in 2007 and led by Said Mark A. Braman, President and CEO, and Dr. Mark Grabowsky, a global health expert in disease prevention and child health, PanTheryx develops and commercializes medical nutrition products that target the gastrointestinal microbiome. The company’s flagship product, DiaResQ®, addresses acute infectious diarrhea, a leading cause of death worldwide among children under the age of five.
In September 2015, PanTheryx announced a multi-country supply and licensing agreement with Dr. Reddy’s Laboratories Ltd. (NYSE: RDY), a global pharmaceutical company.
DiaResQ is now available in the United States on Amazon.com and at Passport Health clinics throughout the country.